874676-81-0

Basic information

• Product Name: 5-Chloro-2-iodopyrimidine
• Synonyms: 5-Chloro-2-iodopyrimidine
• CAS NO: 874676-81-0
• Molecular Formula: C₄H₂ClIN₂
• Molecular Weight: 240.43
• EINECS: 1312995-182-4
• Product Categories: Pyridines, Pyrimidines, Purines and Pteredines;Heterocyclic Compounds;Pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 874676-81-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 316.6 °C at 760 mmHg
• Flash Point: 145.3 °C
• Appearance: White/Powder
• Density: 2.187 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: -2.56±0.22(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Light Sensitive
• CAS DataBase Reference: 5-Chloro-2-iodopyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-2-iodopyrimidine(874676-81-0)
• EPA Substance Registry System: 5-Chloro-2-iodopyrimidine(874676-81-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 874676-81-0(Hazardous Substances Data)

Usage

Uses

Useful Intermediate for organic synthesis and pharmaceutical.

InChI:InChI=1S/C4H2ClIN2/c5-3-1-7-4(6)8-2-3/h1-2H

Upstream product

• 22536-67-0 2,5-dichloropyrimidine 

Downstream Products

• 1204665-20-2 4-(1-(5-chloropyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazine-3-carbonitrile 
• 1204665-23-5 6-(hydroxymethyl)-5-(1-(5-chloropyrimidin-2-yl)piperidin-4-yloxy)-2-(4-(methylsulfonyl)phenyl)pyridazin-3(2H)-one 
• 1221420-59-2 methyl 4-(5-chloropyrimidin-2-yl)-1-(tosyl)-1H-pyrrole-2-carboxylate 
• 1108164-37-9 1-(5-chloropyrimidin-2-yl)piperidin-4-ol 
• 1339944-48-7 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(3-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one 
• 1339944-47-6 BMS₉₀₃₄₅₂ 
• 845618-08-8 5-chloro-2-(trifluoromethyl)pyrimidine 
• 34771-50-1 5-chloro-2-phenylpyrimidine 

Relevant articles and documents

Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection

The development of interferon-free regimens for the treatment of chronic HCV infection constitutes a preferred option that is expected in the future to provide patients with improved efficacy, better tolerability, and reduced risk for emergence of drug-resistant virus. We have pursued non-nucleoside NS5B polymerase allosteric inhibitors as combination partners with other direct acting antivirals (DAAs) having a complementary mechanism of action. Herein, we describe the discovery of a potent follow-up compound (BI 207524, 27) to the first thumb pocket 1 NS5B inhibitor to demonstrate antiviral activity in genotype 1 HCV infected patients, BILB 1941 (1). Cell-based replicon potency was significantly improved through electronic modulation of the pKa of the carboxylic acid function of the lead molecule. Subsequent ADME-PK optimization lead to 27, a predicted low clearance compound in man. The preclinical profile of inhibitor 27 is discussed, as well as the identification of a genotoxic metabolite that led to the discontinuation of the development of this compound.

VIRAL POLYMERASE INHIBITORS

A compound, represented by formula (I) or an enantiomer, diastereoisomer or tautomer thereof : wherein either A or B is nitrogen and the other B or A is C, and the radicals R1, R2, R3, R5, R6, R7, R9, and R10 are as defined herein, or a salt, ester or derivative thereof as viral polymerase inhibitors. The compound is used as an inhibitor of RNA dependent RNA polymerases, particulary those viral polymerases within the Flaviviridae family, more particulary to HCV polymerase.